# US 2002/0119120 A1 · Amino acid substitution mutants of interleukin 13

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0119120 A1
- Document ID: US20020119120A1
- Status: Published application
- Kind: A1
- Application number: 09/938,936
- Filed: 2001-08-24
- Published: 2002-08-29
- Earliest claimed: 1998-04-03
- Assignees: The Pennsylvania State Research Foundation
- Inventors: Waldemar Debinski
- Web page: https://patentgrep.com/patent/US20020119120A1

## CPC

- C07K 14/21: from Pseudomonadaceae (F)
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- C07K 14/5437: {IL-13}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention provides mutant hIL13 molecules include those made by substituting one or more of the amino acid residues that occur in the alpha-helix regions of native hIL13 with various other amino acid residues. Multiply mutated forms of hIL13 conjugated to cytotoxins are used to preferentially target diseased cells over non-diseased cells.

## Claims

### Claim 1

A purified mutant hIL13 molecule comprising an amino acid sequence (a) having at least 90% sequence identity to the native hIL13 sequence (SEQ ID NO:1) and (b) differing from the native hIL13 sequence by at least a first amino acid substitution occurring in the A alpha helix and a second amino acid substitution occurring in the D alpha helix.

### Claim 2

A purified mutant hIL13 molecule comprising an amino acid sequence (a) having at least 90% sequence identity to the native hIL13 sequence (SEQ ID NO:1) and (b) differing from the native hIL13 sequence by at least three amino acid substitutions.

### Claim 3 (depends on 2)

The purified mutant hIL13 molecule of claim 2, wherein the amino acid sequence differs from the native hIL13 sequence by at least a first amino acid substitution occurring in the A alpha helix, a second amino acid substitution occurring in the D alpha helix, and a third amino acid substitution occurring in the C alpha helix.

### Claim 4 (depends on 2)

The purified mutant hIL13 molecule of claim 2, wherein the amino acid sequence differs from the native hIL13 sequence by at least four amino acid substitutions.

### Claim 5 (depends on 4)

The purified mutant hIL13 molecule of claim 4, wherein the amino acid sequence differs from the native hIL13 sequence by at least a first amino acid substitution occurring in the A alpha helix, a second amino acid substitution occurring in the D alpha helix, and a third amino acid substitution occurring in the C alpha helix.

### Claim 6

A purified mutant hIL13 molecule, wherein the molecule comprises a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs:2-9.

### Claim 7

A purified mutant hIL13 molecule, wherein the molecule consists of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs:2-9.

### Claim 8 (depends on 6)

The purified mutant hIL13 molecule of claim 6, wherein the molecule comprises a polypeptide having the amino acid sequence of SEQ ID NO:2.

### Claim 9 (depends on 6)

The purified mutant hIL13 molecule of claim 6, wherein the molecule comprises a polypeptide having the amino acid sequence of SEQ ID NO:3.

### Claim 10 (depends on 6)

The purified mutant hIL13 molecule of claim 6, wherein the molecule comprises a polypeptide having the amino acid sequence of SEQ ID NO:4.

### Claim 11 (depends on 6)

The purified mutant hIL13 molecule of claim 6, wherein the molecule comprises a polypeptide having the amino acid sequence of SEQ ID NO:5.

### Claim 12 (depends on 6)

The purified mutant hIL13 molecule of claim 6, wherein the molecule comprises a polypeptide having the amino acid sequence of SEQ ID NO:6.

### Claim 13 (depends on 6)

The purified mutant hIL13 molecule of claim 6, wherein the molecule comprises a polypeptide having the amino acid sequence of SEQ ID NO:7.

### Claim 14 (depends on 6)

The purified mutant hIL13 molecule of claim 6, wherein the molecule comprises a polypeptide having the amino acid sequence of SEQ ID NO:8.

### Claim 15 (depends on 1)

The purified mutant hIL13 molecule of claim 1, further comprising a pharmaceutically acceptable carrier.

### Claim 16 (depends on 2)

The purified mutant hIL13 molecule of claim 2, further comprising a pharmaceutically acceptable carrier.

### Claim 17 (depends on 6)

The purified mutant hIL13 molecule of claim 6, further comprising a pharmaceutically acceptable carrier.

### Claim 18 (depends on 1)

The purified mutant hIL13 molecule of claim 1, wherein the molecule is conjugated to an effector molecule.

### Claim 19 (depends on 2)

The purified mutant hIL13 molecule of claim 2, wherein the molecule is conjugated to an effector molecule.

### Claim 20 (depends on 6)

The purified mutant hIL13 molecule of claim 6, wherein the molecule is conjugated to an effector molecule.

### Claim 21 (depends on 18)

The purified mutant hIL13 molecule of claim 18, wherein the effector molecule is selected from the group consisting of a cytotoxin, a detectable label, an antibody, a liposome, and a lipid.

### Claim 22 (depends on 21)

The purified mutant hIL13 molecule of claim 21, wherein the effector molecule is a cytotoxin selected from the group consisting of a Pseudomonas exotoxin, Diptheria toxin, ricin, abrin, saporin, and pokeweed viral protein.

### Claim 23 (depends on 22)

The purified mutant hIL13 molecule of claim 22, wherein the cytotoxin is selected from the group consisting of PE38QQR, PE1E, and PE4E.

### Claim 24 (depends on 21)

The purified mutant hIL13 molecule of claim 21, wherein the effector molecule comprises a radionuclide.

### Claim 25 (depends on 19)

The purified mutant hIL13 molecule of claim 19, wherein the effector molecule is selected from the group consisting of a cytotoxin, a detectable label, an antibody, a liposome, and a lipid.

### Claim 26 (depends on 25)

The purified mutant hIL13 molecule of claim 25, wherein the effector molecule is a cytotoxin selected from the group consisting of a Pseudomonas exotoxin, Diptheria toxin, ricin, abrin, saporin, and pokeweed viral protein.

### Claim 27 (depends on 26)

The purified mutant hIL13 molecule of claim 26, wherein the cytotoxin is selected from the group consisting of PE38QQR, PE1E, and PE4E.

### Claim 28 (depends on 25)

The purified mutant hIL13 molecule of claim 25, wherein the effector molecule comprises a radionuclide.

### Claim 29 (depends on 20)

The purified mutant hIL13 molecule of claim 20, wherein the effector molecule is selected from the group consisting of a cytotoxin, a detectable label, an antibody, a liposome, and a lipid.

### Claim 30 (depends on 29)

The purified mutant hIL13 molecule of claim 29, wherein the effector molecule is a cytotoxin selected from the group consisting of a Pseudomonas exotoxin, Diptheria toxin, ricin, abrin, saporin, and pokeweed viral protein.

### Claim 31 (depends on 30)

The purified mutant hIL13 molecule of claim 30, wherein the cytotoxin is selected from the group consisting of PE38QQR, PE1E, and PE4E.

### Claim 32 (depends on 29)

The purified mutant hIL13 molecule of claim 29, wherein the effector molecule comprises a radionuclide.

### Claim 33

A purified nucleic acid encoding a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:2-9.

### Claim 34 (depends on 33)

The purified nucleic acid of claim 33, wherein the polypeptide consists of a sequence selected from the group consisting of SEQ ID NOs:2-9.

### Claim 35 (depends on 1, 2)

An antibody that specifically binds an hIL13 mutant but not a native hIL13, the hIL13 mutant being selected from the group consisting of the mutant hIL13 molecules of claims 1, 2, and 6.

### Claim 36 (depends on 35)

The antibody of claim 35, wherein the hIL13 mutant comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:2-9.

### Claim 37 (depends on 1, 2)

A method of delivering a hIL13 mutant to a cell comprising the steps of:
(a) providing a hIL13 mutant selected from the group consisting of the mutant hIL13 molecules of claims 1, 2, and 6.
(b) providing the cell; and
(c) contacting the cell with the hIL13 mutant.

### Claim 38 (depends on 37)

The method of claim 37, wherein the hIL13 mutant is a polypeptide comprising a sequence selected from the group consisting of SEQ ID NOs:2-9.

### Claim 39 (depends on 38)

The method of claim 38, wherein the hIL13 mutant is conjugated to an effector molecule.

### Claim 43 (depends on 40)

The method of claim 40, wherein the effector molecule is selected from the group consisting of a cytotoxin, a detectable label, an antibody, a liposome, and a lipid.

### Claim 44 (depends on 43)

The method of claim 43, wherein the effector molecule is a cytotoxin selected from the group consisting of a Pseudomonas exotoxin, Diptheria toxin, ricin, abrin, saporin, and pokeweed viral protein.

### Claim 45 (depends on 44)

The method of claim 44, wherein the cytotoxin is selected from the group consisting of PE38QQR, PE1E, and PE4E.

### Claim 46 (depends on 40)

The method of claim 40, wherein the effector molecule comprises a radionuclide.

### Claim 47 (depends on 37)

The method of claim 37, wherein the step (c) of contacting the cell with the hIL13 mutant takes place in an animal.

### Claim 48 (depends on 47)

The method of claim 47, wherein the hIL13 mutant is conjugated to an effector molecule.

### Claim 49 (depends on 47)

The method of claim 47, further comprising the step of administering the hIL13 mutant to the animal.

### Claim 50 (depends on 49)

The method of claim 49, wherein the step of administering the hIL13 mutant to the animal is performed by injection.

### Claim 51 (depends on 37)

The method of claim 37, wherein the cell forms part of a tumor in an animal; the tumor is growing at a measurable rate in the animal; and the rate is decreased subsequent to the step (c) of contacting the cell with the hIL13 mutant.
